Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

2.
3.

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.

Haass C, Selkoe DJ.

Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12. Review.

PMID:
17245412
4.

Conformation-dependent anti-amyloid oligomer antibodies.

Kayed R, Glabe CG.

Methods Enzymol. 2006;413:326-44.

PMID:
17046404
5.

Prefibrillar amyloid aggregates could be generic toxins in higher organisms.

Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, Dobson CM, Stefani M.

J Neurosci. 2006 Aug 2;26(31):8160-7.

7.

Structural properties of Abeta protofibrils stabilized by a small molecule.

Williams AD, Sega M, Chen M, Kheterpal I, Geva M, Berthelier V, Kaleta DT, Cook KD, Wetzel R.

Proc Natl Acad Sci U S A. 2005 May 17;102(20):7115-20. Epub 2005 May 9.

9.

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG.

Science. 2003 Apr 18;300(5618):486-9.

10.

Conformational Abs recognizing a generic amyloid fibril epitope.

O'Nuallain B, Wetzel R.

Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1485-90. Epub 2002 Jan 29.

11.

Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease.

D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH.

Histopathology. 2001 Feb;38(2):120-34.

PMID:
11207825
12.

Antibody-mediated resolution of light chain-associated amyloid deposits.

Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A.

Am J Pathol. 2000 Oct;157(4):1239-46.

13.

Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure.

von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5129-34.

14.

Variant Alzheimer's disease with spastic paraparesis: clinical characterization.

Verkkoniemi A, Somer M, Rinne JO, Myllykangas L, Crook R, Hardy J, Viitanen M, Kalimo H, Haltia M.

Neurology. 2000 Mar 14;54(5):1103-9.

PMID:
10720282
15.

Intraneuronal Abeta42 accumulation in human brain.

Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR.

Am J Pathol. 2000 Jan;156(1):15-20.

16.

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL.

Ann Neurol. 1999 Dec;46(6):860-6.

PMID:
10589538
17.

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J.

Am J Pathol. 1999 Sep;155(3):853-62.

18.

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL.

Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53.

19.
20.

Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.

Harper JD, Wong SS, Lieber CM, Lansbury PT.

Chem Biol. 1997 Feb;4(2):119-25.

Items per page

Supplemental Content

Write to the Help Desk